[go: up one dir, main page]

BR9807112A - Composition, pharmaceutical formulation, combination and use related to the treatment of autoimmune diseases using antigen or tolerant agent in combination with methotrexate - Google Patents

Composition, pharmaceutical formulation, combination and use related to the treatment of autoimmune diseases using antigen or tolerant agent in combination with methotrexate

Info

Publication number
BR9807112A
BR9807112A BR9807112-2A BR9807112A BR9807112A BR 9807112 A BR9807112 A BR 9807112A BR 9807112 A BR9807112 A BR 9807112A BR 9807112 A BR9807112 A BR 9807112A
Authority
BR
Brazil
Prior art keywords
combination
antigen
methotrexate
pharmaceutical formulation
treatment
Prior art date
Application number
BR9807112-2A
Other languages
Portuguese (pt)
Inventor
Howard L Weiner
Ahmad Al-Sabbagh
Patricia A Nelson
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of BR9807112A publication Critical patent/BR9807112A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/21—Ink jet for multi-colour printing
    • B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0094—Colour printing
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0097—Printing on special media, e.g. labels, envelopes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"COMPOSIçãO, FORMULAçãO FARMACêUTICA, COMBINAçãO E USO RELACIONADOS AO TRATAMENTO DE DOENçAS AUTOIMUNES UTILIZANDO ANTìGENO OU AGENTE TOLERANTE EM COMBINAçãO COM METOTREXATO". Uma combinação de um antígeno padrão administrável via mucosa e um metotrexato administrável por via oral, entérica ou parenteral é empregada para produzir uma formulação farmacêutica e para tratar ou prevenir doença autoimune. As quantidades de antígeno padrão e metotrexato são eficazes, em combinação, para suprimir a resposta autoimune associada à doença autoimune."COMPOSITION, PHARMACEUTICAL FORMULATION, COMBINATION AND USE RELATED TO THE TREATMENT OF AUTOIMMUNE DISEASES USING ANTIGEN OR TOLERANT AGENT IN COMBINATION WITH METOTREXATE". A combination of a standard mucosally administrable antigen and an oral, enteric or parenterally administered methotrexate is employed to produce a pharmaceutical formulation and to treat or prevent autoimmune disease. The amounts of standard antigen and methotrexate are effective, in combination, to suppress the autoimmune response associated with autoimmune disease.

BR9807112-2A 1997-01-24 1998-01-26 Composition, pharmaceutical formulation, combination and use related to the treatment of autoimmune diseases using antigen or tolerant agent in combination with methotrexate BR9807112A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3672297P 1997-01-24 1997-01-24
PCT/US1998/001648 WO1998032451A1 (en) 1997-01-24 1998-01-26 Treatment of autoimmune disease using tolerization in combination with methotrexate

Publications (1)

Publication Number Publication Date
BR9807112A true BR9807112A (en) 2001-09-18

Family

ID=21890248

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807112-2A BR9807112A (en) 1997-01-24 1998-01-26 Composition, pharmaceutical formulation, combination and use related to the treatment of autoimmune diseases using antigen or tolerant agent in combination with methotrexate

Country Status (10)

Country Link
EP (1) EP0994717A4 (en)
JP (1) JP2001511134A (en)
KR (1) KR20000070460A (en)
AU (1) AU6648898A (en)
BR (1) BR9807112A (en)
CA (1) CA2278152A1 (en)
HU (1) HUP0001960A2 (en)
IL (1) IL131025A0 (en)
NO (1) NO993600L (en)
WO (1) WO1998032451A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003209095A1 (en) 2002-02-11 2003-09-04 Antares Pharma, Inc. Intradermal injector
EP3495009B2 (en) 2005-01-24 2025-01-15 Antares Pharma, Inc. An injector with prefilled syringe
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
WO2007131013A1 (en) 2006-05-03 2007-11-15 Antares Pharma, Inc. Two-stage reconstituting injector
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
JP5731829B2 (en) 2008-03-10 2015-06-10 アンタレス・ファーマ・インコーポレーテッド Syringe safety device
ES2738539T3 (en) 2008-08-05 2020-01-23 Antares Pharma Inc Multi dose injector
ES2988196T3 (en) 2009-03-20 2024-11-19 Antares Pharma Inc Hazardous agent injection system
ES2705244T3 (en) 2010-06-16 2019-03-22 Inflammatory Response Res Inc Levocetirizine and montelukast for the treatment of influenza and the common cold
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
DK2822618T3 (en) 2012-03-06 2024-01-22 Antares Pharma Inc Pre-filled needle with breaking force function
WO2013152323A1 (en) 2012-04-06 2013-10-10 Wotton Paul K Needle assisted jet injection administration of testosterone compositions
US9364610B2 (en) 2012-05-07 2016-06-14 Antares Pharma, Inc. Injection device with cammed ram assembly
JP2016507305A (en) 2013-02-11 2016-03-10 アンタレス・ファーマ・インコーポレーテッド Needle-assisted jet injection device with reduced trigger force
CA2905031C (en) 2013-03-11 2018-01-23 Hans PFLAUMER Dosage injector with pinion system
WO2014165136A1 (en) 2013-03-12 2014-10-09 Antares Pharma, Inc. Constant volume prefilled syringes and kits thereof
RU2015134422A (en) 2013-03-13 2017-04-18 Инфламматори Респонс Ресёрч, Инк. APPLICATION OF LEVOCYTHIRIZINE AND MONTELUKAST IN THE TREATMENT OF VASCULITIS
ES2770760T3 (en) 2013-03-13 2020-07-03 Inflammatory Response Res Inc Use of levocetirizine and montelukast in the treatment of traumatic injuries
RU2015134423A (en) * 2013-03-13 2017-04-26 Инфламматори Респонс Ресёрч, Инк. APPLICATION OF LEVOCYTHIRISINE AND MONTELUKAST IN TREATMENT OF AUTOIMMUNE DISORDERS
JP2017526728A (en) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド Levocetirizine and montelukast in the treatment of inflammation-mediated conditions
WO2021236518A1 (en) 2020-05-19 2021-11-25 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
AU632991B2 (en) * 1987-06-24 1993-01-21 Autoimmune, Inc. Treatment of autoimmune diseases by oral administration of autoantigens
JPH05507501A (en) * 1990-09-06 1993-10-28 リックスウーニーベルシテイト・テ・ウットレヒト Inhibitors of lymphocyte responses and immune-related diseases
DE69332518T2 (en) * 1992-02-28 2003-09-04 Autoimmune Inc SUPPRESSION OF AUTOIMMUNE DISEASES BY ANTIGENS IN WAITING FORM
WO1996040235A1 (en) * 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Method to use superantigens to target subpopulations of t cells
WO1996041644A1 (en) * 1995-06-13 1996-12-27 Nippon Meat Packers, Inc. Oral remedy for rheumatoid arthritis and functional food

Also Published As

Publication number Publication date
KR20000070460A (en) 2000-11-25
NO993600D0 (en) 1999-07-23
EP0994717A1 (en) 2000-04-26
CA2278152A1 (en) 1998-07-30
JP2001511134A (en) 2001-08-07
EP0994717A4 (en) 2000-07-26
AU6648898A (en) 1998-08-18
HUP0001960A2 (en) 2000-10-28
IL131025A0 (en) 2001-01-28
WO1998032451A1 (en) 1998-07-30
NO993600L (en) 1999-09-23

Similar Documents

Publication Publication Date Title
BR9807112A (en) Composition, pharmaceutical formulation, combination and use related to the treatment of autoimmune diseases using antigen or tolerant agent in combination with methotrexate
BR0108435A (en) Formulation and use of low dose entecavir
BR9106114A (en) METHOD FOR TREATING OR PREVENTING AN AUTOIMMUNE DISEASE (AD) AND PHARMACEUTICAL FORMULATION
KR950002785A (en) Parathyroid hormone and raloxyphene to increase bone mass
KR930702022A (en) Treatment or prevention of type 1 diabetes by oral administration of insulin
BR9811825A (en) Use of lactobacillus to reduce the level of fibrinogen in the blood
CA2299361A1 (en) Use of consensus interferon in combination with il-1 receptor antagonist for treatment of patients afflicted with multiple sclerosis
BR9908030A (en) Pharmaceutical composition comprising one or more orally administered dose units, and processes for preparing it, for use thereof, and for treating a medical condition or disorder in an individual in whom treatment with a cyclooxygenase-2 inhibitor is indicated
HUP9903732A2 (en) Use of cgmp elevators for the preparation of pharmaceutical compositions treating benign prostatic hyperplasia
FR2719999B1 (en) Pharmaceutical composition based on guar gum and a neutralizing antacid, to which can be added a series of therapeutic active ingredients.
BR9815255A (en) Modified botulism toxin, oral vaccine against botulism, oral vaccine against a selected agent and method for administering a therapeutic agent to an animal orally
BR9809951A (en) Method for treating obesity
BR122012014331A8 (en) PHARMACEUTICAL FORMULATIONS
ZA9432B (en) Use of anticonvulsants in the treatment of Parkinson's Disease and Parkinsonian Syndromes
SE8903914D0 (en) ORAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
BR9711194A (en) Use of chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease.
EP0722324A4 (en) PHARMACEUTICAL COMPOSITION FOR USE IN IMMUNE-STRENGTHENING THERAPY
CA2408537A1 (en) Treating irritable bowel syndrome or disease
BR0012444A (en) Dry powder compositions
BRPI0412430A (en) zot and zonulin receptor agonist polypeptide
BR0207704A (en) Modified alpha interferon with reduced immunogenicity
BRPI0409699A (en) methods of inducing the diuretic effect, inducing, maintaining or restoring the diuretic effect of a non-adenosine modifying diuretic, maintaining, restoring or improving renal function in a patient, inducing diuresis, preventing the onset of renal impairment in a patient with fluid or CHF overload, treating CHF patients and improving overall health outcomes, pharmaceutical composition and uses
BR0212249A (en) Compound, pharmaceutical composition, method of treatment or prophylaxis of diseases, and use of a compound
BR0110512A (en) Preparation to measure gastric emptying rate
BR0313503A (en) Restless Leg Syndrome Treatment Method, Adenoin a2a Receptor Antagonist Use, Therapeutic Agent for Restless Leg Syndrome, and Night Myoclonus Treatment Method

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]